SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Drugs that provide the splice of life: Motor neurons relay signals from the nervous system to muscle fibers. In patients with spinal muscular atrophy, a protein required for the survival of these neurons is deficient or missing altogether, so the neurons gradually die and the patients' muscles waste away. The disease is currently untreatable. Naryshkin et al. discovered small-molecule drugs that cause cells to produce the missing protein by altering how a specific mRNA is put together, or “spliced” (see the Perspective by Vigevani and Valcárcel). When the researchers used the drugs to treat diseased mice, the mice showed marked improvement in muscle mass, motor function, and survival. Science , this issue p. 688 ; see also p. 624
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These screens, which are typically conducted in genetically engineered cell lines that harbour the target of interest, led to the discovery of the splice modulators risdiplam106 and branaplam107 for the treatment of spinal muscular atrophy”
From Human disease models in drug development (2023) · cites this paper as [106]
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
GMAP: A genomic mapping and alignment program for mRNA and EST sequences
Wu, T. D., & Watanabe, C. K. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti310 · Cited by 2,354
Fast and SNP-tolerant detection of complex variants and splicing in short reads
Wu, T. D., & Nacu, S. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq057 · Cited by 1,894
Lorson, C. L., Hahnen, E., Androphy, E. J., & Wirth, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6307 · Cited by 1,532
Feldkötter, M., Schwarzer, V., Wirth, R., Wienker, T. F., & Wirth, B. (2002) · The American Journal of Human Genetics · doi:10.1086/338627 · Cited by 1,004
Consensus Statement for Standard of Care in Spinal Muscular Atrophy
Wang, C. H., Finkel, R. S., Bertini, E. S., Schroth, M., Simonds, A., Wong, B., Aloysius, A., Morrison, L., Main, M., Crawford, T. O., et al. (2007) · Journal of Child Neurology · doi:10.1177/0883073807305788 · Cited by 961
Hua, Y., Sahashi, K., Rigo, F., Hung, G., Horev, G., Bennett, C. F., & Krainer, A. R. (2011) · Nature · doi:10.1038/nature10485 · Cited by 741
Cited by
Items 301–400 of 533
Modeling Hematological Diseases and Cancer With Patient-Specific Induced Pluripotent Stem Cells
Kim, H., & Schaniel, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02243 · Cited by 15
Therapeutic advances in 5q-linked spinal muscular atrophy
Reed, U. C., & Zanoteli, E. (2018) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20180011 · Cited by 15
Functional characterization of SMN evolution in mouse models of SMA
Osman, E. Y., Bolding, M., Villalón, E., Kaifer, K. A., Lorson, Z. C., Tisdale, S., Hao, Y., Conant, G. C., Pires, J. C., Pellizzoni, L., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-45822-8 · Cited by 17
Blatnik, A. J., McGovern, V. L., & Burghes, A. H. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168494 · Cited by 13
Arnold, W. D., Duqué, S. I., Iyer, C. C., Zaworski, P. G., McGovern, V. L., Taylor, S. J., von Herrmann, K. M., Kobayashi, D. T., Chen, K. S., Kolb, S. J., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167077 · Cited by 16
Self-citationCarlini, M. J., Triplett, M. K., & Pellizzoni, L. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267990 · Cited by 13
Ilg, M. M., Lapthorn, A. R., Ralph, D. J., & Cellek, S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277646 · Cited by 12
PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice
Kordala, A. J., Stoodley, J., Ahlskog, N., Hanifi, M., Garcia-Guerra, A., Bhomra, A., Lim, W. F., Murray, L. M., Talbot, K., Hammond, S. M., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202317683 · Cited by 14
Innovating spinal muscular atrophy models in the therapeutic era
Signoria, I., van der Pol, W. L., & Groen, E. J. N. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.050352 · Cited by 14
“…Mercuri et al., 2018); (2) onasemnogene abeparvovec-xioi (Zolgensma) is an adenoviral vector-based SMN1 gene-replacement therapy (Mendell et al., 2017; Valori et al., 2010); and (3) risdiplam (Evrysdi) is a small-molecule SMN2 -splicing modifier (Baranello et al., 2021; Naryshkin et al., 2014).”
Spinal Muscular Atrophy (SMA): Treatment strategies, challenges and future prospects
Mishra, N. K., & Mishra, A. (2025) · Pharmacological Research - Reports · doi:10.1016/j.prerep.2025.100031 · Cited by 15
The Druggable Transcriptome Project: From Chemical Probes to Precision Medicines
Disney, M. D. (2025) · Biochemistry · doi:10.1021/acs.biochem.5c00006 · Cited by 11
Maximizing the integration of virtual and experimental screening in hit discovery
Bajusz, D., & Keserű, G. M. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2085685 · Cited by 11
“While the mechanism of action of the resulting hits is obviously less clear, the success of phenotypic drug discovery was demonstrated by first-in-class medicines [86], exemplified by novel treatment options against spinal muscular atrophy [87], cystic fibrosis [88] and hepatitis C [89].”
BackgroundSMN protein is required throughout life to prevent spinal muscular atrophy disease progression
Zhao, X., Feng, Z., Risher, N., Mollin, A., Sheedy, J., Ling, K., Narasimhan, J., Dakka, A., Baird, J. D., Ratni, H., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab220 · Cited by 12
Self-citationTaniguchi‐Ikeda, M., Koyanagi‐Aoi, M., Maruyama, T., Takaori, T., Hosoya, A., Tezuka, H., Nagase, S., Ishihara, T., Kadoshima, T., Muguruma, K., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103140 · Cited by 16
Takata, K., Tomida, J., Reh, S., Swanhart, L. M., Takata, M., Hukriede, N. A., & Wood, R. D. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.677419 · Cited by 12
Rewriting the (tran)script: Application to spinal muscular atrophy
Ratni, H., Mueller, L. A., & Ebeling, M. (2019) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2018.12.003 · Cited by 14
Self-citationTargeting RNA-binding proteins with small molecules: perspectives and challenges
Konde, O. M., Balela, W. B., & Tshitenge, T. B. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2025.1649692 · Cited by 14
Modulators of alternative splicing as novel therapeutics in cancer
Oltean, S. (2015) · World Journal of Clinical Oncology · doi:10.5306/wjco.v6.i5.92 · Cited by 11
Ma, Z., Zou, B., Zhao, J., Zhang, R., Zhu, Q., Wang, X., Xu, L., Gao, X., Hu, X., Feng, W., et al. (2024) · SLAS DISCOVERY · doi:10.1016/j.slasd.2024.100204 · Cited by 11
Pagiazitis, J. G., Delestrée, N., Sowoidnich, L., Sivakumar, N., Simon, C. M., Chatzisotiriou, A., Albani, M., & Mentis, G. Z. (2025) · Cell Reports · doi:10.1016/j.celrep.2024.115147 · Cited by 14
“An antisense oligonucleotide (nusinersen), 108,109 a splice-modifier molecule (risdiplam), 110,111 and SMN replacement by gene therapy (onasemnogene abeparvovec), 112,113 all of which aim to upregulate SMN protein via different mechanisms.”
Belančić, A., Janković, T., Gkrinia, E. M. M., Kristić, I., Bumber, J. R., Rački, V., Pilipović, K., Vitezić, D., & Mršić‐Pelčić, J. (2025) · Neurology International · doi:10.3390/neurolint17030041 · Cited by 15
“…such as amyotrophic lateral sclerosis (ALS), where induced pluripotent stem cell-derived ALS lower MNs show significantly higher terminal deoxynucleotidyl transferase dUTP nick end labeling staining, indicating increased cell death by day 20 of differentiation compared to healthy controls [13].”
Yang, X., Wang, J., Springer, N. A., Zanon, P. R. A., Jia, Y., Su, X., & Disney, M. D. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf231 · Cited by 10
“…developed to displace proteins bound to RNA repeat expansions, thereby alleviating gain-of-function disorders [ 7 ], to direct pre-messenger RNA (mRNA) splicing outcomes [ 8–10 ], and to increase RNA turnover by affecting retention of introns or inclusion of a pre-mature termination codon [ 11 ].”
Affecting RNA biology genome-wide by binding small molecules and chemically induced proximity
Baisden, J. T., Childs‐Disney, J. L., Ryan, L. S., & Disney, M. D. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.03.006 · Cited by 12
Targeting RNA with small molecules—A safety perspective
Lightfoot, H. L., & Smith, G. F. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16027 · Cited by 11
Baek, J., Jeong, H., Ham, Y., Jo, Y. H., Choi, M., Kang, M.-G., Son, B., Choi, S., Ryu, H. W., Kim, J., et al. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.153089 · Cited by 11
The Role of Mutant RNA in the Pathogenesis of Huntington’s Disease and Other Polyglutamine Diseases
Bogomazova, A. N., Валерьевич, Е. А., Pozmogova, G. E., & Lagarkova, M. A. (2019) · Molecular Biology · doi:10.1134/s0026893319060037 · Cited by 11
Aikawa, T., Watanabe, T., Miyazaki, T., Mikuni, T., Wakamori, M., Sakurai, M., Aizawa, H., Ishizu, N., Watanabe, M., Kano, M., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx193 · Cited by 12
“Because repeat-expanded MPI-type channels play a causative role in SCA6 pathogenesis, decreasing its production by altering the splice patterns at this locus, possibly by pharmacological intervention, could emerge as a potential therapeutic strategy for SCA6, as in the case of spinal muscular atrophy (37) and Alzheime…”
Application of induced pluripotent stem cells to primary immunodeficiency diseases
Karagiannis, P., Yamanaka, S., & Saito, M. K. (2019) · Experimental Hematology · doi:10.1016/j.exphem.2019.01.005 · Cited by 14
Signoria, I., Zwartkruis, M. M., Geerlofs, L., Perenthaler, E., Faller, K. M. E., James, R., McHale-Owen, H., Green, J. W., Kortooms, J. V., Snellen, S. H., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101379 · Cited by 12
“A meta-analysis of real-world studies on nusinersen illustrated that outcomes vary signi fi - cantly: 10% of patients experiencing a further decline, while others achieved new motor milestones or stabilized.”
Pagliari, E., Taiana, M. M., Manzini, P., Sali, L., Quetti, L., Bertolasi, L., Oldoni, S., Melzi, V., Comi, G. P., Corti, S. P., et al. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05550-3 · Cited by 12
Christinat, Y., Pawłowski, R., & Krek, W. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw145 · Cited by 13
“…the very encouraging reports on the recent development of orally available small molecule splicing modifiers for the treatment of spinal muscular atrophy (Naryshkin et al. , 2014), it will be exciting to explore the possibility of targeting MKNK2 alternative splicing as a line of therapy in cancer.”
BackgroundHammond, S. M., Abendroth, F., Gait, M. J., & Wood, M. J. A. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9670-4_13 · Cited by 10
Star, E., Stevens, M., Gooding, C., Smith, C. W. J., Li, L., Ayine, M., Harper, S. J., Bates, D. O., & Oltean, S. (2021) · Oncogenesis · doi:10.1038/s41389-021-00323-0 · Cited by 10
Aasdev, A., Sreelekshmi, R. S., Iyer, V. R., & Moharir, S. C. (2024) · Journal of Biosciences · doi:10.1007/s12038-023-00412-9 · Cited by 14
The Future of Computational Chemogenomics
Jacoby, E., & Brown, J. B. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8639-2_15 · Cited by 10
Rozza, R., Janoš, P., Spinello, A., & Magistrato, A. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2114452 · Cited by 12
Zhao, X., Gong, Z., Luo, H., Li, Z., Gao, R., Yang, K., Deng, W., Peng, S., Ba, L., Liu, Y., et al. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03515-0 · Cited by 9
Self-citationThree- and four-stranded nucleic acid structures and their ligands
Hashimoto, Y., Shil, S., Tsuruta, M., Kawauchi, K., & Miyoshi, D. (2025) · RSC Chemical Biology · doi:10.1039/d4cb00287c · Cited by 15
Splice-switching small molecules: A new therapeutic approach to modulate gene expression
Taladriz‐Sender, A., Campbell, E., & Burley, G. A. (2019) · Methods · doi:10.1016/j.ymeth.2019.06.011 · Cited by 10
“molecules which induce a Exon 7 inclusion in SMN2.[33, 34] The PTC/Roche team has”
BackgroundBroad variation in response of individual introns to splicing inhibitors in a humanized yeast strain
Hunter, O., Talkish, J., Quick-Cleveland, J., Igel, H., Tan, A., Kuersten, S., Katzman, S. J., Donohue, J. P., Jurica, M. S., & Ares, M. (2023) · RNA · doi:10.1261/rna.079866.123 · Cited by 11
Axonal and Neuromuscular Junction Pathology in Spinal Muscular Atrophy
Boyd, P. J., & Gillingwater, T. H. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803685-3.00008-2 · Cited by 14
Osman, E. Y., Rietz, A., Kline, R., Cherry, J. J., Hodgetts, K. J., Lorson, C. L., & Androphy, E. J. (2019) · Scientific Reports · doi:10.1038/s41598-018-38208-9 · Cited by 9
Small-molecule modulators of protein–RNA interactions
Byun, W. G., Lim, D., & Park, S. B. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102149 · Cited by 13
Mammalian Models of Spinal Muscular Atrophy
Burghes, A. H. M., DiDonato, C. J., McGovern, V. L., & Arnold, W. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803685-3.00015-x · Cited by 10
Genetics of Spinal Muscular Atrophy
Burghes, A. H. M., & McGovern, V. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802257-3.00006-7 · Cited by 11
Spinal Muscular Atrophy: Current Medications and Re-purposed Drugs
Basak, S., Biswas, N., Gill, J. M., & Ashili, S. (2024) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-024-01511-3 · Cited by 9
Olenginski, L. T., Attionu, S. K., Henninger, E. N., LeBlanc, R. M., Longhini, A. P., & Dayie, T. K. (2023) · Viruses · doi:10.3390/v15091913 · Cited by 8
“Several recent in vitro [208] and in silico [209] high-throughput screening (HTS) methods have identified chemotypes that selectively bind RNA motifs with physiological effects in cell culture and animal models.”
BackgroundBar-Chama, N. C., Elsheikh, B., Hewamadduma, C., Guittari, C. J., Gorni, K., & Mueller, L. A. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00626-5 · Cited by 9
La atrofia muscular espinal en el nuevo escenario terapéutico
Tizzano, E. F. (2018) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2018.08.001 · Cited by 15
Gao, D., Morini, E., Salani, M., Krauson, A. J., Ragavendran, A., Erdin, S., Logan, E. M., Chekuri, A. K., Li, W., Dakka, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.03.932103 · Cited by 8
Self-citationSignificance of gene therapy in neurodegenerative diseases
Wang, L., Ma, L., Gao, Z., Wang, Y., & Qiu, J. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1515255 · Cited by 12
Sun, C., Zhang, L., Zhang, L., Song, Y., Ma, B., & Wang, Y. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c00605 · Cited by 7
Advances in iPSC Technology in Neural Disease Modeling, Drug Screening, and Therapy
Dai, S., Qiu, L., Veeraraghavan, V. P., Sheu, C., & Mony, U. (2023) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x18666230608105703 · Cited by 9
Manipulating cell fate while confronting reproducibility concerns
Osterloh, J. M., & Mullane, K. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.016 · Cited by 7
Chen, S., Priebbenow, D. L., Somkhit, J., Scullino, C. V., Agama, K., Pommier, Y. G., & Flynn, B. L. (2022) · Chemistry - A European Journal · doi:10.1002/chem.202201925 · Cited by 6
Joyce, C. L. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.030 · Cited by 10
“The pipeline for SMA therapeutics comprises novel treatment modalities (antisense oligos and gene therapy) as well as classic drug discovery approaches to treatment development (Naryshkin et al., 2014 and Cherry et al., 2014).”
MethodEmpirical drug discovery: a view from the proteome
Lee, J. A., Carragher, N. O., & Berg, E. L. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.05.003 · Cited by 7
Translating from Proteins to Ribonucleic Acids for Ligand‐binding Site Detection
Moeller, L., Guerci, L., Isert, C., Atz, K., & Schneider, G. (2022) · Molecular Informatics · doi:10.1002/minf.202200059 · Cited by 8
Zhong, Z., Jiang, Y., Zhao, L., Wang, Y., & Zhang, Z. (2022) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2022.109528 · Cited by 7
In utero genetic therapy: Treatment of early onset neurological disorders before they start
Borges, B., Brown, S. M., MacKenzie, T. C., & Sumner, C. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.012 · Cited by 6
U1 snRNP Biogenesis Defects in Neurodegenerative Diseases
Campagne, S. (2024) · ChemBioChem · doi:10.1002/cbic.202300864 · Cited by 7
Mechanisms of functional improvement behind nusinersen treatment in adult spinal muscular atrophy
Hsieh, P.-F., Lai, H., Kuo, Y.-C. J., Yang, C., Huang, P.-Y., Ting, C.-H., Tai, S.-T., Kao, C.-H., Tsai, Y.-C., Huang, H.-W., et al. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115230 · Cited by 8
Romancing the Spliceosome to Fight Spinal Muscular Atrophy
Swoboda, K. J. (2014) · New England Journal of Medicine · doi:10.1056/nejmcibr1409795 · Cited by 6
Zhang, L., Abendroth, F., & Vázquez, O. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00161 · Cited by 7
Determination of RNA-ligand interactions with the photoaffinity platform PEARL-seq
Sexton, A. N., Vandivier, L. E., Petter, J. C., Mukherjee, H., & Blain, J. C. (2022) · Methods · doi:10.1016/j.ymeth.2022.06.009 · Cited by 6
Therapeutic potential of orphan drugs for the rare skeletal muscle diseases
Swiderski, K., & Lynch, G. S. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1085858 · Cited by 7
Neuromuscular diseases: progress in gene discovery drives diagnostics and therapeutics
Fratta, P., & Hanna, M. G. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70239-x · Cited by 6
Granatosky, E. A., DiPrimio, N., Pickering, J. R. E., Stevens, D. C., Perlstein, E. O., & Taylor, R. E. (2018) · Journal of Natural Products · doi:10.1021/acs.jnatprod.8b00314 · Cited by 7
Gentillon, C., Connell, A. J., Kirk, R. W., & Butchbach, M. E. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180657 · Cited by 6
Мутантная РНК: роль в патогенезе болезни Гентингтона и других полиглутаминовых заболеваний
Bogomazova, A. N., Валерьевич, Е. А., Pozmogova, G. E., & Lagarkova, M. A. (2019) · Molecular Biology · doi:10.1134/s002689841906003x · Cited by 6
Vigevani, L., & Valcárcel, J. (2014) · Science · doi:10.1126/science.1258444 · Cited by 6
Wooley, J. R., Crowder, M. E., Pyles, N. J., & Sumner, C. J. (2017) · Wiley eBooks · doi:10.1002/9781118661895.ch16 · Cited by 6
Chao, K.-H., Mao, A., Liu, A., Salzberg, S. L., & Pertea, M. (2025) · eLife · doi:10.7554/elife.107454 · Cited by 13
“Notably, Duchenne muscular dystrophy ( Aartsma-Rus et al., 2002 ; McClorey et al., 2005 ) and spinal muscular atrophy ( Burnett et al., 2009 ; Lorson et al., 1999 ; Naryshkin et al., 2014 ) are well-known examples of disorders arising from splicing defects.”
Mechanistic studies of small molecule ligands selective to RNA single G bulges
Hegde, S., Akhter, S., Tang, Z., Qi, C., Yu, C., Lewicka, A., Liu, Y., Koirala, K., Reibarkh, M., Battaile, K. P., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf559 · Cited by 7
“…risdiplam and branaplam, both targeting precursor messenger RNA (pre-mRNA)-U1 small nuclear ribonucleoprotein (snRNP) complex, attracted tremendous attention as RNA splicing modulators to treat genetic diseases, including spinal muscular atrophy [ 11–17 ] and Huntington’s disease [ 18–20 ].”
Miller, N., Xu, Z., Quinlan, K. A., Ji, A., McGivern, J. V., Feng, Z., Shi, H., Ko, C., Tsai, L., Heckman, C. J., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2300308120 · Cited by 7
Self-citationTreatment of Adult Spinal Muscular Atrophy: Overview and Recent Developments
Brakemeier, S., Stolte, B., Kleinschnitz, C., & Hagenacker, T. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220329115433 · Cited by 6
Palacios, D. S. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01491 · Cited by 6
Spinal Muscular Atrophy Therapeutics Development
Sunshine, S., Jarecki, J., MacKenzie, A., & Chen, K. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803685-3.00016-1 · Cited by 6
Self-citationSkeletal Muscle in Spinal Muscular Atrophy As an Opportunity for Therapeutic Intervention
Verche, V. L., Sunshine, S., Hammers, D. W., Sweeney, H. L., & Paushkin, S. V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803685-3.00021-5 · Cited by 6
Self-citationApplication of urine cells in drug intervention for spinal muscular atrophy
Zhang, Q., Lin, X., Li, J.-J., Lu, Y., Guo, X.-X., Dong, E., Zhao, M., He, J., Wang, N., & Chen, W. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4791 · Cited by 6
Nerve sprouting capacity in a pharmacologically induced mouse model of spinal muscular atrophy
Rimer, M., Seaberg, B. L., Yen, P., Lam, S., Hastings, R. L., Lee, Y. I., Thompson, W. J., Feng, Z., Metzger, F., Paushkin, S. V., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-44222-2 · Cited by 5
Self-citation25 years of the SMN genes: the Copernican revolution of spinal muscular atrophy.
Tiziano, F. D., & Tizzano, E. F. (2020) · PubMed Central · doi:10.36185/2532-1900-037 · Cited by 8
Programmable technologies to manipulate gene expression at the RNA level
Liu, H., Rauch, S., & Dickinson, B. C. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.03.004 · Cited by 7
A meditation on accelerating the development of small molecule medicines targeting RNA
Yang, X., Childs‐Disney, J. L., & Disney, M. D. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2084528 · Cited by 6
“Chemical matter starting points for Risdiplam were discovered from a luciferase-based phenotypic screen followed by a medicinal chemistry campaign optimizing the lead molecule to afford the FDA-approved drug [9,10].”
BackgroundFullenkamp, C. R., Liang, X., Pettersson, M., & Schneekloth, J. S. (2024) · Methods and principles in medicinal chemistry · doi:10.1002/9783527840458.ch13 · Cited by 5
Sel, E. K., Gkrinia, E. M. M., Roncato, R., Vitezić, D., Јаnkovic, S., & Belančić, A. (2025) · Journal of International Medical Research · doi:10.1177/03000605251397777 · Cited by 5
Wu, J., Yan, S., Bian, Y., Liu, R., Lyu, X., Zhang, Z., Huang, S., Chen, T., & Cheng, L. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70133 · Cited by 4
“Both in vivo and in vitro experiments have shown that Risdiplam can cross the blood–brain barrier, increase levels of functional SMN protein, and improve survival rates, body weight, and motor function (Naryshkin et al. 2014; Poirier et al. 2018).”
NADPH oxidase 4 inhibition is a complementary therapeutic strategy for spinal muscular atrophy
Khoury, M. E., Biondi, O., Bruneteau, G., Sapaly, D., Bendris, S., Bézier, C., Clerc, Z., Akar, E. A., Weill, L., Eid, A. A., et al. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1242828 · Cited by 6
“Finally, a number of unsuitable off-targets were detected with Evrysdi, leading to perturbations in the transcriptome of targeted tissues (Naryshkin et al., 2014).”
BackgroundOtsuki, N., Kato, T., Yokomura, M., Urano, M., Matsuo, M., Kobayashi, E., Haginoya, K., Awano, H., Takeshima, Y., Saito, T., et al. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03597-4 · Cited by 4
A Chemically Induced CRISPR/dCas13FCPF Platform for Precise and Programmable RNA Regulation
Hasselbeck, S., Wang, J., Bai, Z., Hüfner, T., Hummer, G., Grote, P., & Cheng, X. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01609 · Cited by 4
Small Molecule Approaches to Upregulate SMN Expression From the SMN2 Locus
Cherry, J. J., Calder, A. N., Hodgetts, K. J., & Androphy, E. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803685-3.00017-3 · Cited by 5
Woll, M. G., Naryshkin, N. A., & Karp, G. M. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2017_12 · Cited by 4
Self-citationA click chemistry assay to identify natural product ligands for pre-microRNAs
Garner, A. L., Lorenz, D. A., & Gallagher, E. E. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.04.020 · Cited by 4
“…the discovery of ribocil, a synthetic ligand for the FMN riboswitch (Howe et al., 2015), and RNA-binding SMN-C and NVS-SM1 SMN2 splicing modulators (Naryshkin et al., 2014; Palacino et al., 2015; Sivaramakrishnan et al., 2017), have provided recent evidence for the potential druggability of RNA.”
BackgroundThe Evolution of Stem Cells, Disease Modeling, and Drug Discovery for Neurological Disorders
Pernia, C. D., Tobe, B. T. D., O'Donnell, R., & Snyder, E. Y. (2020) · Stem Cells and Development · doi:10.1089/scd.2019.0217 · Cited by 4
Screening for small molecule inhibitors of HIV-1 Gag expression
Balachandran, A., & Cochrane, A. (2017) · Methods · doi:10.1016/j.ymeth.2017.06.007 · Cited by 4
Potential Use of Stem Cells in Mood Disorders
Colpo, G. D., Stertz, L., Diniz, B. S., & Teixeira, A. L. (2018) · Advances in experimental medicine and biology · doi:10.1007/5584_2018_250 · Cited by 4
Identification of p38 MAPK inhibition as a neuroprotective strategy for combinatorial SMA therapy
Carlini, M. J., Espinoza‐Derout, J., Alstyne, M. V., Tisdale, S., Workman, E., Triplett, M. K., Tattoli, I., Yadav, S., Henderson, C. E., Watterson, D. M., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00303-6 · Cited by 7
Gampe, C. M., Wörsdörfer, B., Zou, G., & Ricci, A. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00676 · Cited by 4
Modulation of prion protein expression through cryptic splice site manipulation
Gentile, J. E., Corridon, T. L., Mortberg, M. A., D’Souza, E. N., Whiffin, N., Minikel, E. V., & Vallabh, S. M. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107560 · Cited by 4
Disulfide Tethering to Map Small Molecule Binding Sites Transcriptome-wide
Moon, M. H., Vock, I. W., Streit, A. D., Connor, L. J., Senkina, J., Ellman, J. A., & Simon, M. D. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00538 · Cited by 3
Metadata
- Authors
- Naryshkin, N. A., Weetall, M., Dakka, A., Narasimhan, J., Zhao, X., Feng, Z., Ling, K. K. Y., Karp, G. M., Qi, H., Woll, M. G., Chen, G., Zhang, N., Gabbeta, V., Vazirani, P., Bhattacharyya, A., Furia, B., Risher, N., Sheedy, J., Kong, R., Ma, J., Turpoff, A., Lee, C.-S., Zhang, X., Moon, Y.-C., Trifillis, P., Welch, E. M., Colacino, J. M., Babiak, J., Almstead, N. G., Peltz, S. W., Eng, L. A., Chen, K. S., Mull, J. L., Lynes, M. S., Rubin, L. L., Fontoura, P., Santarelli, L., Haehnke, D., McCarthy, K. D., Schmucki, R., Ebeling, M., Sivaramakrishnan, M., Ko, C.-P., Paushkin, S. V., Ratni, H., Gerlach, I., Ghosh, A., & Metzger, F.
- Affiliations
- PTC Therapeutics (United States) (US)
- University of Southern California (US)
- Spinal Muscular Atrophy Foundation (US)
- Harvard University (US)
- F. Hoffmann-La Roche AG (CH)
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Grenzacherstrasse 124, 4070 Basel, Switzerland.
- Corresponding author
- Peltz, Stuart W.
- Metzger, Friedrich
- ORCID
- Naryshkin, Nikolai A.
- Weetall, Marla
- Narasimhan, Jana
- Zhao, Xin
- Ling, Karen K. Y.
- Chen, Guangming
- Zhang, Nanjing
- Sheedy, Josephine
- Kong, Ronald
- Ma, Jiyuan
- Moon, Young-Choon
- Welch, Ellen M.
- Colacino, Joseph M.
- Peltz, Stuart W.
- Chen, Karen S.
- Rubin, Lee L.
- Fontoura, Paulo
- Ebeling, Martin
- Ko, Chien-Ping
- Paushkin, Sergey V.
- Ratni, Hasane
- Metzger, Friedrich
- Venue
- Science
- Published
- 2014-08-08
- Volume
- 345
- Issue
- 6197
- Pages
- 688-693
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1992985034
- Cited by
- 524
- References
- 56
- Citations by year
- 2026: 19 · 2025: 40 · 2024: 47 · 2023: 33 · 2022: 50 · 2021: 54 · 2020: 34 · 2019: 47 · 2018: 50 · 2017: 44 · 2016: 59 · 2015: 35 · 2014: 12
- FWCI
- 25.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Keywords
- spinal muscular atrophy, SMN2, SMN1, alternative splicing, small molecules, SMN protein, motor function, lifespan extension, neuromuscular degeneration, compound screening
- MeSH terms
- Administration, Oral, Animals, Cells, Cultured, Coumarins, Disease Models, Animal, Drug Evaluation, Preclinical, Humans, Longevity, Muscular Atrophy, Spinal, Pyrimidinones, RNA, Messenger, Sequence Deletion, Alternative Splicing, Isocoumarins, Mice, Small Molecule Libraries, Survival of Motor Neuron 2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.